Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment
Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is
often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response
to anti-vascular agents differs from the response of typical AMD.
This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV
patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).